Johnson & Johnson’s MedTech Segment Shines with Impressive Q3 Growth

Johnson & Johnson's third-quarter performance exceeded expectations, with adjusted EPS of $2.42 against an expected $2.19. source: https://tokenist.com/johnson-johnsons-medtech-segment-shines-with-exceeding-sales-growth-in-q3/?utm_source=rss&utm_medium=rss&utm_campaign=johnson-johnsons-medtech-segment-shines-with-exceeding-sales-growth-in-q3